TABLE 7.
Mean predicted inhibition (%) of analytes 1 hour post‐dose in part A a of the study (safety population b )
| Analyte | Placebo (N = 23) mean % (SE) | 1 mg (N = 5) mean % (SE) | 3 mg (N = 3) mean % (SE) | 10 mg (N = 6) mean % (SE) | 20 mg (N = 6) mean % (SE) | 30 mg (N = 6) mean % (SE) | 40 mg (N = 6) mean % (SE) |
|---|---|---|---|---|---|---|---|
| MCP‐1 | 11 (±10) | 9 (±14) | 27 (−) | 18 (±9) | 19 (±10) | 42 (±12) | 75 (±13) |
| IL‐6 | 10 (±6) | 13 (±6) | 14 (±8) | −1 (±7) | 16 (±13) | 14 (±8) | 5 (±6) |
| TNF | 15 (±9) | 34 (±17) | 15 (±17) | −1 (±11) | 47 (±24) | 36 (±13) | 34 (±18) |
Abbreviations: IL‐6, interleukin‐6; MCP‐1, monocyte chemoattractant protein‐1; SE, standard error; TNF, tumour necrosis factor.
a
Part A was a single ascending‐dose crossover study in two interlocking cohorts. Each participant received a maximum of two single ascending oral doses of GSK3358699 (1, 3, 10, 20, 40 or 30 mg) and one dose of placebo.
b
The safety population consisted of all randomized participants who received at least one dose of study treatment.